Epigenetics Market Size, Share & Industry Analysis, By Product Type (Instruments, Consumables), By Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Others), By Application (Oncology, Infectious Diseases, Cardiovascular Diseases, Others), By End User (Academic & Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organisations, Others)Others and Regional Forecast, 2024-2032

Epigenetics is an innovative field dealing with identifying and monitoring, the phenotypic changes in genes due to changes in the chromosomes, wherein the DNA sequence is not been affected. This field is generally implicated in the study of cancer, although other applications are expanding. Rising institutional and governmental collabration, and funding for development of new methods for disease diagnosis and treatment, are some of the factors anticipated to increase the demand for epignetics and hence driving the growth of the market. For instance, in February 2016, the University of Southampton and University Hospitals Southampton NHS Foundation Trust (UK) received USD 1.57 million (GBP 1 million) for genetics and genomics research related to cancer and infectious diseases.

Rising prevalnce of cancer globally along with growing applications epigenetics in non-oncology diseaes are some of the major factor driving the growth of the global epigentics market. According to WHO estimates, people suffering from cancer is expected to increase to 19.3 million by 2025 from 14.1 million in 2012. According to the American Cancer Society, in the U.S., the number of new cancer cases increased to 1,688,780 in 2017 from 1,685,210 in 2016.

However, the high cost of epigenetics instruments is one of the major factor hindering the market growth. For instance, Illumina’s NovaSeq 5000 and 6000 sequencers (launched in January 2017) are priced at USD 850,000 and USD 985,000, respectively.

Market Segmentation:

By product type, the market is segmented into instruments, and consumables (enzymes, reagents, kits, etc.). Based on technology the market is segmented into DNA methylation, histone methylation, histone acetylation and others. Based on application, the market is segmented into oncology, infectious diseases, cardiovascular diseases and others. Based on end users, the epigenetics market is segmented into academic & research institutes, pharmaceutical and biotechnology companies, contract research organisations and others.

From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Players Covered:

The major companies in the global epigenetics market report includes Illumina, Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., and Novartis AG. and others.

Key Insights

• Prevalence of Cancer, Chronic Diseases, By Key Regions/ Key Countries, 2018


• New Product Launches, Key Players


• Key Industry Development, such as Mergers & Applications

Regional Analysis:

The global epigenetics market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe dominated the global epigenetics market in 2018, owing to strong funding by government for research activities on epigenetics. Additionally, presence of advanced healthcare facilities and advancements in diagnostic procedures are some of the factor stimulating the growth of the regional market.

For instance, in March 2015, Barts Cancer Institute’s Centre for Haemato-Oncology (UK) received funds worth USD 113.9 million (GBP 860,000) from the Medical Research Council to study epigenetics changes in cancer. Asia Pacific is estimated to witness a significant growth during forecast period due to rising disposable income, high unmet clinical needs of patients, increasing awareness about early diagnosis in emerging countries, such as India and China. Latin America and the Middle East and Africa are anticipated to hold significant share in epigenetics market during the forecast period of 2019-2026.

Segmentation

Epigenetics Industry Developments

• In January 2017, BASF SE, established an interdisciplinary innovation platform on epigenetics and launched Dermagenist, first active ingredient to reverse methylation in fibroblasts.


• In October 2017, Cambridge Epigenetix and NuGEN Technologies entered into partnership through which NuGEN will market the U.K. firm’s TrueMethyl oxidative bisulfite sequencing (oxBS-Seq) kits for epigenetic marker identification and quantification, and incorporate the technology into next-generation sequencing (NGS) library preparation kits.